Adalvo announces the successful DCP approval for Apixaban Tablets.
Based on the reference brand Eliquis, Apixaban is indicated for the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). As per IQVIA, total global Apixaban sales for 2023 was $27.7Bn with a 3Y CAGR of 9%.
With this approval, Adalvo is well-positioned to bring Apixaban Tablets to market as a crucial treatment option for patients suffering from DVT and PE.
The DCP approval of Apixaban Tablets reflects Adalvo's commitment to delivering high-quality, differentiated treatments to our partners. Our rigorous development process ensures that we meet the highest standards of safety and efficacy, providing a reliable alternative for patients in need.
There are no half-measures at Adalvo – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!